SCHEMBL26239498

SCHEMBL26239498

CC(C)COC(=O)Nc1ncnn2c([C@@H]3O[C@](C)(CO)[C@H]4OC(C)(C)O[C@@H]34)ccc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LCK P06239 2/20 0.33
▸ KDR P35968 2/20 0.33
▸ TMPRSS2 O15393 1/20 0.32
▸ KDM4E B2RXH2 2/20 0.31
▸ CSNK2A2 P19784 1/20 0.31
▸ CSNK2A1 P68400 1/20 0.31
▸ MAPK1 P28482 1/20 0.30
▸ TSHR P16473 1/20 0.30
▸ FSHR P23945 1/20 0.30
▸ ABL1 P00519 1/20 0.30
▸ RET P07949 1/20 0.30
▸ HCK P08631 1/20 0.30
▸ KIT P10721 1/20 0.30
▸ SRC P12931 1/20 0.30
▸ PDGFRA P16234 1/20 0.30
▸ TEK Q02763 1/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26823411 0.91 TMPRSS2 (0.35) LCKKDRTMPRSS2
SCHEMBL26288320 0.87 EGLN2 (0.33) TMPRSS2
SCHEMBL26235345 0.86 LCK (0.35) LCKKDRTMPRSS2KDM4ECSNK2A2
SCHEMBL26832567 0.84 TMPRSS2 (0.37) LCKKDRTMPRSS2MAPK1
SCHEMBL26237130 0.80 MAOB (0.31) LCKKDRTMPRSS2MAPK1
SCHEMBL26823086 0.79 TMPRSS2 (0.40) LCKKDRTMPRSS2MAPK1RET
SCHEMBL16710444 0.78 NPSR1 (0.32) TMPRSS2
SCHEMBL26236660 0.78 POLRMT (0.37) —
SCHEMBL23803200 0.77 TMPRSS2 (0.38) TMPRSS2
SCHEMBL19101802 0.77 TMPRSS2 (0.38) TMPRSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382940-A1 ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. 2023-11-30 — — US disclosed
WO-2023168254-A1 ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. (US) 2023-09-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382940-A1 ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME EIF2AK2, MAVS, ZC3HAV1 LCK 2502/4885KDR 4246/4885TMPRSS2 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback